Premium
Anti‐VEGF for treatment of macular edema secondary to retinal vein occlusions
Author(s) -
MENDRINOS E
Publication year - 2011
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2011.3114.x
Subject(s) - ranibizumab , medicine , macular edema , ophthalmology , edema , randomized controlled trial , retinal , central retinal vein occlusion , anesthesia , surgery , bevacizumab , chemotherapy
Purpose To assess efficacy and safety of intraocular injections of 0.3 mg or 0.5 mg ranibizumab in patients with macular edema following branch and central retinal vein occlusion. Methods Prospective, randomized, sham injection‐controlled, double‐masked, multicenter clinical trials. Six‐month (monthly injections) and one year (PRN) results of the BRAVO and CRUISE studies will be presented. Results In the BRAVO study, mean change from baseline BCVA letter score at month 6 was 16.6 and 18.3 in the 0.3 mg and 0.5 mg ranibizumab groups and 7.3 in the sham group (P<0.0001). At 12 months, the corresponding change was 16.4, 18.3 and 12.1 letters respectively.The percentage of patients who gained > or =15 letters in BCVA at month 12 was 56% (0.3 mg) and 60.3% (0.5 mg) in the ranibizumab groups and 43.9% in the sham group; and CFT had decreased by a mean of 314 microm (0.3 mg) and 347 microm (0.5 mg) in the ranibizumab groups and 274 microm in the sham group). In the CRUISE study, mean change from baseline BCVA letter score at month 6 was 12.7 and 14.9 in the 0.3 mg and 0.5 mg ranibizumab groups, respectively, and 0.8 in the sham group (P<0.0001).At 12 months, the corresponding change was 13.9, 13.9 and 7.3 letters respectively.The percentage of patients who gained > or =15 letters in BCVA at month 12 was 47% (0.3 mg) and 50.8% (0.5 mg) in the ranibizumab groups and 33.1% in the sham group;CFT had decreased by a mean of 453 microm (0.3 mg) and 462 microm (0.5 mg) in the ranibizumab groups and 427 microm in the sham group). Conclusion Intraocular injections of 0.3 mg or 0.5 mg ranibizumab provid rapid, effective treatment for macular edema following BRVO and CRVO with low rates of ocular and nonocular safety events